Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUE-DDGP in T/NK Cell Lymphoma-associated Hemophagocytic Syndrome
NCT04999878Phase 4Unknown
- Sponsor
- Zhengzhou University
- Start
- May 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ruxolitinib in hemophagocytic lymphohistiocytosis (HLH), T-cell lymphoma, natural killer cell lymphoma (NKCL), sponsored by Zhengzhou University. Status: unknown.
02
Drugs
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)T-cell lymphomanatural killer cell lymphoma (NKCL)
Beyond the preview
Go deeper on NCT04999878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999878.